JaLCDOI 10.18926/AMO/32410
FullText URL fulltext.pdf
Author Ohnoshi, Taisuke| Hiraki, Shunkichi| Nakata, Yasunari| Machida, Ken-ichi| Fujii, Masafumi| Nakata, Yasunori| Murakami, Naoki| Miyake, Ken-ichi| Harada, Jun-ichi| Ozawa, Shiro| Seto, Takumi| Tamura, Tetsuo| Kimura, Ikuro|
Abstract <p>Forty-one patients with small cell carcinoma of the lung were treated with a four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine. The response rate was 68% (28 responded among 41 patients), with 10 complete responses (24%) and 18 partial responses (44%). The median survival time from the initiation of chemotherapy was 11 months for patients with limited disease and 8 months for those with extensive disease. Patients who achieved complete response survived significantly longer than those who did not; the median survival time for complete responders was 14.5 months, compared to 8.5 months for partial responders and 6 months for non-responders. Myelosuppressive toxicity remained within acceptable limits, with 5% incidence of leukocytopenia (less than 1,000/microliter) and 7% incidence of thrombocytopenia (less than 50,000/microliter) following the first course of the regimen.</p>
Keywords small cell lung cancer combination chemotherapy
Amo Type Article
Published Date 1983-04
Publication Title Acta Medica Okayama
Volume volume37
Issue issue2
Publisher Okayama University Medical School
Start Page 147
End Page 153
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 6307001
Web of Sience KeyUT A1983QN63900007
JaLCDOI 10.18926/AMO/32200
FullText URL fulltext.pdf
Author Ohnoshi, Taisuke| Hiraki, Shunkichi| Ueda, Nobuo| Fujii, Masafumi| Machida, Ken-ichi| Ueoka, Hiroshi| Kawahara, Shin| Kozuka, Akira| Kiura, Katsuyuki| Moritaka, Tomonori| Kodani, Tsuyoshi| Kamei, Haruhito| Kimura, Ikuro|
Abstract <p>Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.</p>
Keywords non-small cell lung cancer ifosfamide cisplatin vindesine
Amo Type Article
Published Date 1991-10
Publication Title Acta Medica Okayama
Volume volume45
Issue issue5
Publisher Okayama University Medical School
Start Page 357
End Page 361
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 1661559
Web of Sience KeyUT A1991GN53800010
JaLCDOI 10.18926/AMO/30448
FullText URL fulltext.pdf
Author Haruta, Yuro| Takahashi, Isao| Sekito, Noriko| Miyamoto, Kanji| Shimamoto, Masaaki| Wakita, Yoshiharu| Kikkawa, Kiyoshi| Nakamura, Toru| Seto, Takumi| Yamashita, Jiro| Yorimiysu, Seiichi| Miyake, Susumu| Machida, Ken-ichi| Kimura, Ikuro|
Abstract <p>A rare case of variant Philadelphia (Ph1) chromosome positive [46, XX, t (9; 22) (q34; q11), inv (9) (9q22; 22q13)] chronic myelocytic leukemia (CML) was described. The patient, 73 years old female, was hospitalized to our hospital because of leukocytosis. Hematological findings corresponded to those of CMLs. However, this case lacked hepatosplenomegaly. Southern blot analysis using a 3 breakpoint cluster region (bcr) probe revealed a bcr rearrangement. The patient has been in the chronic phase for sixteen months without treatment. Clinical and chromosomal changes are under observation in order to get accumulate data for a pathophysiological analysis of variant Ph1 positive CMLs.</p>
Keywords variant Ph1 positive chronic myelocytic leukemia bcr rearrangement
Amo Type Article
Published Date 1990-10
Publication Title Acta Medica Okayama
Volume volume44
Issue issue5
Publisher Okayama University Medical School
Start Page 283
End Page 286
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 2260501
Web of Sience KeyUT A1990EG00700009